Beovu (brolucizumab-dbll) / Novartis, Santen, China Medical System - LARVOL DELTA

Real-world efficacy and safety of Brolucizumab injection in vitrectomised eyes (BIVE) - a prospective multicentric study. (PubMed, BMC Ophthalmol) - No abstract available

Journal • Real-world evidence

Off-label intravitreal brolucizumab and bevacizumab for chronic central serous chorioretinopathy. (PubMed, Int J Ophthalmol) - "Brolucizumab is anatomically and functionally superior to bevacizumab in the treatment of patients with cCSC."

Journal • Retinal Disorders

Intraocular Inflammation After Intravitreal Faricimab Injections: A Case Series. (PubMed, Clin Exp Ophthalmol) - "Non-infectious hypertensive uveitis can occur subacutely after intravitreal faricimab injections. It is imperative that intraocular pressure is promptly managed to reduce the risk of permanent glaucomatous damage. As all our patients presented with anterior vitreous involvement, it is also practical that such cases of IOI are not mistaken for infectious exogenous endophthalmitis to avoid unnecessary treatment with intravitreal antibiotics and surgery."

Journal • Glaucoma • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis

Two-in-one protein tag enables the soluble expression and calcium-dependent purification of single-chain antibody fragments. (PubMed, Commun Biol) - "Importantly, the anti-VEGF-scFv produced with the CSQ-tag showed a binding affinity of 25.8 pM, similar to that of the existing therapeutic brolucizumab. Therefore, CSQ-tag can significantly improve productivity and simultaneously maintain scFvs' functional integrity, thereby serving as a promising tool for universal expression and purification of therapeutic scFvs."

Journal

Regional association between PM2.5 exposure and anti-VEGF treatment demand for age-related macular degeneration: a nationwide ecological study in Japan. (PubMed, Environ Sci Pollut Res Int) - "This nationwide analysis revealed a significant association between regional PM2.5 levels and the use of anti-VEGF intravitreal injections for macular diseases. No such relationship was observed for SOX, NOX, or PMD. These findings suggest that PM2.5 may contribute to the regional demand for AMD treatment, highlighting the need for further investigation into the impact of air pollution on ocular health."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Two year outcomes of as needed brolucizumab therapy in exudative age related macular degeneration with or without pachychoroid phenotype. (PubMed, Sci Rep) - "Although the number of additional injections was comparable between the two groups in the first 12 months (1.2 ± 1.4 vs. 1.7 ± 1.6, p = 0.29), the number of additional injections was significantly lower in the pachychoroid phenotype than in the non-pachychoroid phenotype (1.5 ± 2.4 vs. 3.2 ± 2.6, p = 0.0098) in the second 12 months. In the 24-month as-needed brolucizumab treatment group, the response to the pachychoroid phenotype was favorable, with significant BCVA improvement and fewer additional injections, particularly in the second 12 months."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Real-world database evaluation of drug-associated vitreous opacities and machine learning for clinical interpretability. (PubMed, Front Cell Dev Biol) - "The five highest-risk drugs were dexamethasone, brolucizumab, triamcinolone, faricimab, and fingolimod. This first systematic real-world evaluation of VO-related adverse drug reactions identifies high-risk drugs, susceptible populations, and onset patterns, thus offering guidance for preventive medication strategies. The BAG model showed higher sensitivity in real-world analysis, suggesting potential for further research in VO and floater prevention and treatment."

Journal • Real-world evidence

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. (PubMed, Invest Ophthalmol Vis Sci) - "The purpose of this study was to evaluate short-term intraocular blood flow changes post-intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in patients with neovascular age-related macular degeneration (nAMD), compare reductions across 4 agents (brolucizumab, faricimab, aflibercept 2 mg, and aflibercept 8 mg), and examine correlations between each agent's molar dose and the magnitude of 30-minute blood flow change. Aflibercept 8 mg produced a significant 30-minute reduction in ocular blood flow. Choroidal flow reduction was greater than with aflibercept 2 mg and negatively correlated with molar dose, suggesting a concentration-dependent hemodynamic effect."

Journal • Retrospective data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. (PubMed, PLoS One) - "Aflibercept 2 mg was the most common drug used overall from 2017-2023. Faricimab had the highest absolute and relative increase in utilization from 2022-2023. Patients with Medicare B or C were significantly more likely to receive aflibercept over bevacizumab."

Journal • Medicare • Reimbursement • Retrospective data • US reimbursement • Ophthalmology

VEGF-inhibitor switch trial in poor-responsive neovascular age-related macular degeneration: assessing brolucizumab vs. faricimab: VISTA study. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "In poor-responsive nAMD, switching to BRZ or FAR under a TAE regimen without upload achieved stable vision, sustained CST reduction, and comparable treatment burden over one year. FAR showed greater fvPED regression and a slight functional trend, while BRZ achieved faster fluid resolution with fewer injections."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Quantitative optical coherence tomography angiography biomarkers Following a Switch to Brolucizumab in Neovascular age-related macular degeneration. (PubMed, Korean J Ophthalmol) - "Intravitreal brolucizumab demonstrated favorable anatomical improvements and maintained visual outcomes over 12 months. Quantitative OCTA biomarkers, particularly FD, may serve as imaging indicators of disease activity and treatment response in eyes with nAMD undergoing a therapy switch."

Biomarker • Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen. (PubMed, Sci Rep) - No abstract available

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Short-Term Outcomes of Intravitreal Brolucizumab Injection and Sub-Tenon Injection of Triamcinolone Acetonide for Diabetic Macular Edema: A Pilot Study. (PubMed, J Vitreoretin Dis) - " Combination therapy with intravitreal brolucizumab and sub-Tenon triamcinolone acetonide may offer anatomic benefits in patients with DME, requiring fewer injections. Further evaluation using larger, prospectively designed studies is warranted to confirm its functional efficacy and long-term safety."

Journal • Diabetic Macular Edema • Inflammation • Ophthalmology

Comparison of Three Consecutive Monthly Administrations Between Aflibercept 8 mg and Brolucizumab 6 mg in Polypoidal Choroidal Vasculopathy. (PubMed, Pharmaceuticals (Basel)) - "Complete regression of polypoidal lesions was observed in 62.5% and 75.0% of patients in the aflibercept and brolucizumab groups, respectively (p = 0.57). During the induction phase, aflibercept 8 mg demonstrated comparable outcomes to brolucizumab 6 mg in reducing CRT and SCT, achieving a dry macula, improving BCVA, and regressing polypoidal lesions in eyes with PCV."

Journal • Age-related Macular Degeneration

Laser Speckle Flowgraphy (LSFG) in Age-Related Macular Degeneration and Diabetic Retinopathy: A Systematic Review of Recent Literature. (PubMed, J Clin Med) - "Anti-VEGF injections produced acute reductions in MBR, particularly with brolucizumab, with partial recovery over time; drug-specific differences suggest a potential impact on geographic atrophy progression... LSFG provides reproducible, rapid, and non-invasive quantitative insights into ocular hemodynamics across degenerative retinal diseases. Its integration into multimodal imaging may facilitate early diagnosis, support personalized management, and assist in the prognostic assessment of retinal and choroidal vascular disorders."

Journal • Review • Age-related Macular Degeneration • Cardiovascular • Diabetic Macular Edema • Diabetic Retinopathy • Dry Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema. (clinicaltrials.gov) - P4 | N=63 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Active, not recruiting | Phase classification: P ➔ P4

Enrollment closed • Phase classification • Diabetic Macular Edema • Ophthalmology

Analysis the frequency of using Aflibercept (8 mg) in the treatment of neovascular age-related macular degeneration and diabetic macular edema compared with other anti-VEGF agents (PubMed, Vestn Oftalmol) - "The use of aflibercept 8 mg in the treatment of nAMD and DME demonstrates a reduction in the number of intravitreal injections, accompanied by a significant reduction in the socioeconomic burden."

Clinical • Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Factors associated with patient-initiated discontinuation of anti-vascular endothelial growth factor therapy for diabetic macular edema: a real-world study in Japan. (PubMed, Jpn J Ophthalmol) - "The findings of this study underscore the importance of individualized patient management strategies to enhance long-term adherence to anti-VEGF therapy among patients with DME."

Journal • Real-world evidence • Diabetic Macular Edema • Ophthalmology

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration. (PubMed, Eye (Lond)) - "The Week 64 results in TALON reaffirmed those reported at Week 32, demonstrating extended treatment intervals and an overall favourable benefit/risk profile for brolucizumab in patients with nAMD."

Journal • P3 data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration (Nature) - "At Week 64, more brolucizumab patients had a last treatment interval of q16w with no DA vs aflibercept (28.4% vs 12.2%). In the brolucizumab arm, 22.4%, 26.0% and 23.2% of patients were on treatment intervals of 12, 8 and 4 weeks (on SoC after USM), respectively, compared with 23.9%, 22.0% and 41.8% in the aflibercept arm. The average change in best-corrected visual acuity (letters) from baseline at Weeks 60 and 64 was comparable (brolucizumab: +4.7; aflibercept: +4.9). Average change in central subfield thickness (µm) at Weeks 60 and 64 was −182.9 µm in the brolucizumab arm vs −167.5 µm with aflibercept."

P3 data • Age-related Macular Degeneration

SPARROW: Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD (clinicaltrials.gov) - P=N/A | N=80 | Active, not recruiting | Sponsor: Berner Augenklinik | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

PROUD: Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - P3 | N=148 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Monotherapy • Trial completion • Age-related Macular Degeneration

Central retinal vein occlusion following intravitreal injections: a case series highlighting multifactorial risk. (PubMed, Int J Retina Vitreous) - No abstract available

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion

A Randomised-controlled trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in patients with Chronic Central Serous Chorioretinopathy with persistent fluid in the absence of choroidal neovascular membrane - BRICS trial Report II. (PubMed, Am J Ophthalmol) - "Brolucizumab resulted in rapid resolution of fluid in chronic CSCR without CNVM, associated with significant reduction in CMT and SFCT. Long-term studies will help understand recurrence patterns and adverse effect profile."

Journal • Retinal Disorders

Intraocular Cytokine Level Prediction from Fundus Images and Optical Coherence Tomography. (PubMed, Sensors (Basel)) - "Diseases included 64 exudative age-related macular degeneration, 29 brolucizumab-associated endophthalmitis, 19 cataract surgeries, 15 retinal vein occlusion, and 8 diabetic macular edema...No significant difference was observed between CFP and OCT (p = 0.9281). Notably, VEGF showed low predictability (31st with CFP, 12th with OCT)."

Journal • Age-related Macular Degeneration • Cataract • Diabetic Macular Edema • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration